PURPOSE OF REVIEW: Since the discovery two decades ago that programmable endonucleases can be engineered to modify human cells at single nucleotide resolution, the concept of genome editing was born. Now these technologies are being applied to therapeutically relevant cell types, including hematopoietic stem cells (HSC), which possess the power to repopulate an entire blood and immune system. The purpose of this review is to discuss the changing landscape of genome editing in hematopoietic stem cells (GE-HSC) from the discovery stage to the preclinical stage, with the imminent goal of clinical translation for the treatment of serious genetic diseases of the blood and immune system. RECENT FINDINGS: With the discovery that the RNA-programmable (sgRNA) clustered regularly interspace short palindromic repeats (CRISPR)-Cas9 nuclease (Cas9/sgRNA) systems can be easily used to precisely modify the human genome in 2012, a genome-editing revolution of hematopoietic stem cells (HSC) has bloomed. We have observed that over the last 2 years, academic institutions and small biotech companies are developing HSC-based Cas9/sgRNA genome-editing curative strategies to treat monogenic disorders, including β-hemoglobinopathies and primary immunodeficiencies. We will focus on recent publications (within the past 2 years) that employ different genome-editing strategies to 'hijack' the cell's endogenous double-strand repair pathways to confer a disease-specific therapeutic advantage. SUMMARY: The number of genome-editing strategies in HSCs that could offer therapeutic potential for diseases of the blood and immune system have dramatically risen over the past 2 years. The HSC-based genome-editing field is primed to enter clinical trials in the subsequent years. We will summarize the major advancements for the development of novel autologous GE-HSC cell and gene therapy strategies for hematopoietic diseases that are candidates for curative allogeneic bone marrow transplantation.
PURPOSE OF REVIEW: Since the discovery two decades ago that programmable endonucleases can be engineered to modify human cells at single nucleotide resolution, the concept of genome editing was born. Now these technologies are being applied to therapeutically relevant cell types, including hematopoietic stem cells (HSC), which possess the power to repopulate an entire blood and immune system. The purpose of this review is to discuss the changing landscape of genome editing in hematopoietic stem cells (GE-HSC) from the discovery stage to the preclinical stage, with the imminent goal of clinical translation for the treatment of serious genetic diseases of the blood and immune system. RECENT FINDINGS: With the discovery that the RNA-programmable (sgRNA) clustered regularly interspace short palindromic repeats (CRISPR)-Cas9 nuclease (Cas9/sgRNA) systems can be easily used to precisely modify the human genome in 2012, a genome-editing revolution of hematopoietic stem cells (HSC) has bloomed. We have observed that over the last 2 years, academic institutions and small biotech companies are developing HSC-based Cas9/sgRNA genome-editing curative strategies to treat monogenic disorders, including β-hemoglobinopathies and primary immunodeficiencies. We will focus on recent publications (within the past 2 years) that employ different genome-editing strategies to 'hijack' the cell's endogenous double-strand repair pathways to confer a disease-specific therapeutic advantage. SUMMARY: The number of genome-editing strategies in HSCs that could offer therapeutic potential for diseases of the blood and immune system have dramatically risen over the past 2 years. The HSC-based genome-editing field is primed to enter clinical trials in the subsequent years. We will summarize the major advancements for the development of novel autologous GE-HSC cell and gene therapy strategies for hematopoietic diseases that are candidates for curative allogeneic bone marrow transplantation.
Authors: Daniel E Bauer; Sophia C Kamran; Samuel Lessard; Jian Xu; Yuko Fujiwara; Carrie Lin; Zhen Shao; Matthew C Canver; Elenoe C Smith; Luca Pinello; Peter J Sabo; Jeff Vierstra; Richard A Voit; Guo-Cheng Yuan; Matthew H Porteus; John A Stamatoyannopoulos; Guillaume Lettre; Stuart H Orkin Journal: Science Date: 2013-10-11 Impact factor: 47.728
Authors: Suk See De Ravin; Linhong Li; Xiaolin Wu; Uimook Choi; Cornell Allen; Sherry Koontz; Janet Lee; Narda Theobald-Whiting; Jessica Chu; Mary Garofalo; Colin Sweeney; Lela Kardava; Susan Moir; Angelia Viley; Pachai Natarajan; Ling Su; Douglas Kuhns; Kol A Zarember; Madhusudan V Peshwa; Harry L Malech Journal: Sci Transl Med Date: 2017-01-11 Impact factor: 17.956
Authors: Beatriz E Marciano; Christine Spalding; Alan Fitzgerald; Daphne Mann; Thomas Brown; Sharon Osgood; Lynne Yockey; Dirk N Darnell; Lisa Barnhart; Janine Daub; Lisa Boris; Amy P Rump; Victoria L Anderson; Carissa Haney; Douglas B Kuhns; Sergio D Rosenzweig; Corin Kelly; Adrian Zelazny; Tamika Mason; Suk See DeRavin; Elizabeth Kang; John I Gallin; Harry L Malech; Kenneth N Olivier; Gulbu Uzel; Alexandra F Freeman; Theo Heller; Christa S Zerbe; Steven M Holland Journal: Clin Infect Dis Date: 2014-12-23 Impact factor: 9.079
Authors: Megan D Hoban; Gregory J Cost; Matthew C Mendel; Zulema Romero; Michael L Kaufman; Alok V Joglekar; Michelle Ho; Dianne Lumaquin; David Gray; Georgia R Lill; Aaron R Cooper; Fabrizia Urbinati; Shantha Senadheera; Allen Zhu; Pei-Qi Liu; David E Paschon; Lei Zhang; Edward J Rebar; Andrew Wilber; Xiaoyan Wang; Philip D Gregory; Michael C Holmes; Andreas Reik; Roger P Hollis; Donald B Kohn Journal: Blood Date: 2015-03-02 Impact factor: 22.113
Authors: Michael C Gundry; Lorenzo Brunetti; Angelique Lin; Allison E Mayle; Ayumi Kitano; Dimitrios Wagner; Joanne I Hsu; Kevin A Hoegenauer; Cliona M Rooney; Margaret A Goodell; Daisuke Nakada Journal: Cell Rep Date: 2016-10-25 Impact factor: 9.423
Authors: Carmen F Bjurström; Michelle Mojadidi; John Phillips; Caroline Kuo; Stephen Lai; Georgia R Lill; Aaron Cooper; Michael Kaufman; Fabrizia Urbinati; Xiaoyan Wang; Roger P Hollis; Donald B Kohn Journal: Mol Ther Nucleic Acids Date: 2016 Impact factor: 8.886
Authors: Jianbin Wang; Colin M Exline; Joshua J DeClercq; G Nicholas Llewellyn; Samuel B Hayward; Patrick Wai-Lun Li; David A Shivak; Richard T Surosky; Philip D Gregory; Michael C Holmes; Paula M Cannon Journal: Nat Biotechnol Date: 2015-11-09 Impact factor: 54.908
Authors: Jianbin Wang; Joshua J DeClercq; Samuel B Hayward; Patrick Wai-Lun Li; David A Shivak; Philip D Gregory; Gary Lee; Michael C Holmes Journal: Nucleic Acids Res Date: 2015-11-02 Impact factor: 16.971
Authors: Erik R Westin; David S Tsao; Oguzhan Atay; Brian P Landry; Patrick P Ye; Devon Chandler-Brown; Brian Alford; Jennifer Hoskovec; Akila Subramaniam; Kevin M Pawlik; Spencer G Kuper; Frederick D Goldman; Tim M Townes; Vivien A Sheehan Journal: Am J Hematol Date: 2022-05-02 Impact factor: 13.265
Authors: Valentina Capo; Maria Carmina Castiello; Elena Fontana; Sara Penna; Marita Bosticardo; Elena Draghici; Luigi P Poliani; Lucia Sergi Sergi; Rosita Rigoni; Barbara Cassani; Monica Zanussi; Paola Carrera; Paolo Uva; Kerry Dobbs; Nicolò Sacchetti; Luigi D Notarangelo; Niek P van Til; Gerard Wagemaker; Anna Villa Journal: J Allergy Clin Immunol Date: 2017-12-11 Impact factor: 10.793
Authors: Gustavo de Alencastro; Francesco Puzzo; Mara Pavel-Dinu; Feijie Zhang; Sirika Pillay; Karim Majzoub; Matthew Tiffany; Hagoon Jang; Adam Sheikali; M Kyle Cromer; Ruhikanta Meetei; Jan E Carette; Matthew H Porteus; Katja Pekrun; Mark A Kay Journal: Mol Ther Date: 2020-10-22 Impact factor: 11.454